ARTICLE | Clinical News
Boceprevir meets HCV endpoints
August 5, 2010 12:29 AM UTC
Merck & Co. Inc. (NYSE:MRK) said two Phase III trials of boceprevir to treat HCV met their primary endpoints. In both trials, the HCV NS3/4A protease inhibitor plus PegIntron peginterferon alfa-2b and...